Author

K. Oishi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Research Focus:host-pathogen & immune response· 4 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1

Frequent Co-Authors

H. Tani· 3 shared M. Itamochi· 3 shared N. Inasaki· 3 shared S. Yazawa· 3 shared T. Shimada· 3 shared Y. Saga· 3 shared B. tenOever· 2 shared E. Yamazaki· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

H. Tani

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Neutralizing antibody levels and epidemiological information of patients with breakthrough COVID-19 infection in Toyama, Japan

H. Tani, N. Inasaki, T. Shimada, Y. Saga, H. Kaya, Y. Maruyama, S. Matano, H. Itoh, T. Kashii, E. Yamazaki, S. Yazawa, M. Itamochi, K. Oishi

This study examines neutralizing antibody levels and epidemiological data of patients with breakthrough COVID-19 infections in Toyama, Japan, finding that Omicron BA.1 variants show minimal neutralization despite prior vaccination.

bioRxiv · Feb 27, 2023Microbiology

Evaluation of SARS-CoV-2 isolation in cell culture from nasal/nasopharyngeal swabs or saliva specimens of patients with COVID-19

S. Yazawa, E. Yamazaki, Y. Saga, M. Itamochi, N. Inasaki, T. Shimada, K. Oishi, H. Tani

This study evaluates SARS-CoV-2 isolation efficiency from nasal/nasopharyngeal swabs and saliva, finding lower efficiency in saliva due to inhibitory factors like lactoferrin and amylase.

bioRxiv · Feb 16, 2023 · PreprintMicrobiology

Activation of SARS-CoV-2 by trypsin-like proteases in the clinical specimens of patients with COVID-19

E. Igarashi, T. Shimada, S. Yazawa, Y. Saga, M. Itamochi, N. Inasaki, Y. Morinaga, K. Oishi, H. Tani

This study examines how trypsin-like proteases affect SARS-CoV-2 infectivity in clinical specimens, finding significant increases for the delta variant compared to omicron.

bioRxiv · Sep 27, 2022 · PreprintMicrobiology

SARS-CoV-2 infection results in lasting and systemic perturbations post recovery

J. J. Frere, R. A. Serafini, K. D. Pryce, M. Zazhytska, K. Oishi, I. Golynker, M. Panis, J. Zimering, S. Horiuchi, D. A. Hoagland, R. Moller, A. Ruiz, J. B. Overdevest, A. Kodra, P. D. Canoll, , B. tenOever

This study compares short- and long-term systemic responses to SARS-CoV-2 and IAV in golden hamsters, finding persistent inflammation in olfactory tissues post-recovery.

bioRxiv · Jan 18, 2022Microbiology

Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics

L. Si, H. Bai, M. Rodas, W. Cao, C. Y. Oh, A. Jiang, R. Moller, D. Hoagland, K. Oishi, S. Horiuchi, S. Uhl, D. Blanco-Melo, R. A. Albrecht, W.-C. Liu, T. Jordan, , D. E. Ingber

This paper demonstrates the use of human organ chips to rapidly repurpose therapeutics for viral pandemics, identifying amodiaquine as a potential treatment for SARS-CoV-2.

bioRxiv · Apr 13, 2020 · PreprintMicrobiology

Engineering an RNA-based tissue-specific platform for genetic editing through use of a miRNA-enabled Cas12a

R. Moeller, K. Oishi, B. tenOever

This paper develops an RNA-based CRISPR-Cas12a system that enables tissue-specific genetic editing with reduced immunogenicity through miRNA-dependent crRNA maturation and self-inactivation.

bioRxiv · Mar 4, 2020 · PreprintBioengineering